

# INFORMATION DISCLOSURE CITATION IN AN **APPLICATION** (PTO-1449)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)					ATTY. DOCKET NO. 114232.109  APPLICANT Leland SHAPIRO  FILING DATE March 3, 2000			Leland SHAPIRE SHEET 1 OF  SERIAL NO. 09/518,076  GROUP 1614													
														S LUS PATE	NT DO	CUMENTS:	验			7.14.00	
											AMINER'S	;	PATENT NO.	DATE		NAME		CLASS		BCLASS	LITIUG
AM	AA	4,657,763	4/14/87	Fink	elstein et al.	1	CLASS	1	BCLA33	DATE											
	AB	4,732,973	3/22/88	1	r et al	1		$\sqcap$													
	A C	4,839,283	6/13/89	Kaw	asaki et al	П	· <u>-</u> ·	$\sqcap$													
	AD	5,166.134	11/24/92	Lezo	ley et al.																
	AE	5,476,995	12/19/95	Clar	k et al																
	AF	5,489,593	2/6/96	Palm	ner et al.			$\Box$													
	AG	5,504,095	4/2/96	Nak	ane et al.																
	AH	5,529,920	6/25/96	Cole	et al.		1		<del>`</del>												
	ΑĪ	5,565,334	10/15/96	Kufe	et al		1		<b>\</b>												
	AJ	5,567,682	10/22/96	Pert		_	<del>\</del>	$\vdash$	<del>\</del>												
-	AK	5,604,201	2/18/97	Thor	nas et al.		<del>-\</del>	-	+ 1												
	AL	5,641,670	6/24/97	-	o et al		<del>-\</del>	_	<del></del>												
	AM	5,665,589	9/9/97		is et al			-	-												
_   -	AN	5,780,009	7/14/98	<del></del>	tzas et al		<del></del>		-\-												
	AO	5,804,594	9/8/98	Mura		<del></del>	<del>- \                                   </del>	<del>                                     </del>	-+	<b></b> -											
1	AP	5,817,484	10/6/98	Yu e	<del></del>				-+												
V	AQ	5,914,342	6/22/99	_	rer et al.			_		······································											
V																					
•																					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



### Leland SHAPIRO SHEET 2 OF 4

INFORMATION DISCLOSURE CITATION IN AN APPLICATION					ATTY. DO	OCKET NO. 19		SERIAL NO. 09/518,076	
					APPLICA Leland	101 M			
	(PTO-1449)					ATE 00	GROUP 1614		101 3 80 80 80 80 80 80 80 80 80 80 80 80 80
	No.		FOREIGN PA	TENT	DOCUMENT	SAMO			3
EXAMINER'S INITIALS	'	PATENT NO.	DATE	c	OUNTRY	CLASS	SUBCLASS	Translation Yes No	8
_ wA	BA	WO95/28422	10/26/95	PC1		\	1		1
	ВВ	WO95/34538	12/21/95	PCT					1
	вс	WO96/12021	4/25/96	PC1					1
	BD	WO96/14067	5/17/96	PCI			\		1
	BE	WO97/31937	9/4/97	PCT					
	BF	WO00/52034	/		_		\		
W	BG	WO99/43308	9/2/99	-					
v	вн	WO94/07525 ~	/	wo		1	1 ,		
		ļ							
			<u> </u>	<u> </u>					
			<u> </u>	-					
-				$\vdash$					
									i
EXAMINER	<u> </u>	000	1/1X	D,	ATE CONS	IDERED	) Y	1	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





## INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO. 114232.109

SERIAL NO. 09/518,076

APPLICANT

Leland SHAPIRO

FILING DATE May 3, 2000 GROUP 1614

		May 3, 2000							
	10.71	Ana AvOTHERART (Including Author, Title, Date, Perlineut Pages, Etc.)							
my	CA	Altieri, D.C. J Leukoc Biol 1995, 58, 120127							
	СВ	Animal Cell Culture, R. I. Freshney, ed., 1986							
	cc	Auerswald et al., "Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication", Bio Chem Hoppe Seyler, 375(10):695-703 (1994)							
	Beal, M.F., "Mitochondria, Free Radicals, and Neurodegeneration", Curr. Opin. Neurobiol., 1996, 6, 661-666								
	CE	Beck, K.F. et al. in J Exp Biol 1999, 202, 64553							
	CF	Cilberto et al., 1995, Cell, 41:531-540							
	CC	Deigner, H.P. and R. Kinscherf, "Modulating Apoptosis: Current Applications and Prospects for Future Drug Development", Curr Med Chem 1999, 6, 399-414							
	СН	Dery, O. and Bunnett, N.W. Biochem Soc Trans 1999, 27,246-254							
	CI	Dery, O. et al. Am J Physiol 1998, 2 74, C 1429-C 1452							
	ច	Ding, A. et al., in J. Immunol. 1990, 145, 940							
•	СК	Goureau, 0. et al., in Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4276							
	Gu M, Rappaport J, Leppla SH., "Furin is important but not essential for the proteolytimaturation of gp160 of HIV-1", FEBS Lett, 22;365(1):95-7 (May 10, 1995)								
	СМ	Heck, D. E. et al., in J. Biol. Chem. 1990, 267, 21277							
	CN	Inocencio et al., "Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-KI cells", J Biol Chem, 272(2):1344-8 (1997)							
	со	Jabs, Thorsten, "Reactive Oxygen Intermediates as Mediators of Programmed Cell Deat in Plants and Animals", Biochem Pharmacol 1999 57, 231-245							
,	Kaufmann, Scott H., Serge Desnoyers, Yvonne Ottaviano, Nancy E. Davidson G. Poirier, "Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: A Marker of Chemotherapy-induced Apoptosis", Cancer Res 1993, 53, 3976								
	cQ	Kidd, Vincent J., PROTEOLYTIC ACTIVITIES THAT MEDIATE APOPTOSIS, Annu Rev Physiol, 1998, 60, 533							
	CR	Kido H, Niwa Y, Beppu Y, Towatari T. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul 1996;36:325-47							
	cs	Kirkeboen, K.A. and Strand, O.A. in Acta Anaesthesiol Scand 1999, 43, 275							
	СТ	Langer, R. Nature 1998, 392, 5							
XAMINE	R	DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in onformance and not considered. Include copy of this form with next communication to Applicant.



## Leland SHAPIRO SHEET 4 OF 4

<b>1</b> 4	MATION DISCLOSURE	ATTY. DOCKET NO. 114232.109	SERIAL NO. 09/518,076  CHOW				
ll.	ITATION IN AN APPLICATION	APPLICANT Leland SHAPIRO					
	(PTO-1449)	FILING DATE May 3, 2000	GROUP 1614				
	OTHER ART (Including Author, Ti	le, Date, Pertinent Pages, Etc.)					
₩ cn	Best, P.J.M., et al., Arterioscler Thromb Vasc Biol 1999, 19, 14						
CV	Lomas DA, Elliott PR, Carrell RW. Commercial plasma alphal-antitrypsin (Prolastin) contains a conformationally inactive, latent component. Eur Respir J 1997 Mar;10(3):672-5						
CW	Lowenstein, C. J. and Snyder, S.H. in Cell 1992, 70, 705-707						
сх	Lowenstein C. J. et al. in Proc. Natl. Acad. Sci. USA, 1993, 90, 9730						
CY	McCall, T.B. et al., in Biochem. Biophys. Res. Commun. 1992,186, 680						
· CZ	Meylan et al., "HIV infectivity is not augmented by treatment with trypsin, Factor Xa or human mast-cell tryptase", AIDS, 6(1):128-30 (1992)						
САА	Miranda et al., "Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes", Proc Natl Acad Sci U S A, 93(15):7695-7700) (1996)						
CAB	Molle W. et al. in J Immunol 1997, 159, 3555						
CAC	Morel, J. B. and Dangle, J.L., Cell Death Differ 1997, 4, 67 1						
- CAD	Nathan, C. in FASEB J. 1992, 6, 3051						
CAE	Ohnishi et al., "A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1", J Virol, 68(6):4075-99 (1994)						
CAF	Okumura et al., "The extracellular processing of HIV-1 envelope glycoprotein gp160 by human plasmin", FEBS Lett, 442(1):39-42 (1998)						
CAG	Patel R.P., et al. in Biochim Biophys Acta 1999, 1411, 385-400						
САН	Popko B. and Baerwald, K. D. in Neurochem Res 1999, 24, 33 1 (Abstract)						
CAI	)						
CAJ	Punjabi, C. J. et al., in J. Immunol. 199						
, CAK	Remington's Pharmaceutical Sciences 1990, pp. 1519-1675, Gennaro, A. R., ed., Mack Publishing Company, Easton, PA.						
CAL	Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.						
CAM	Schini et al. in Circ Res 1994, 74, 24						
CAN	Schwartz, et al., "Antiviral activity of the proteasome on incoming human immunodeficiency virus type I", J Virol, 72(5):3845-50) (1998)						
\I CAO	Smith, M. E. in Neurochem Res 1999,						
V CAP	Wood, E.R. et al. in Biochem Biophys		7-74				
EXAMINER		ATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.